Silo Pharma, Inc. (SILO) — This stock currently has no analyst coverage. No price targets, ratings, or earnings estimates are available. This is common for preferred shares, warrants, OTC-traded securities, and smaller companies that are not followed by Wall Street analysts.
分析师预估 每股收益(EPS)为 $-0.56 和 营收为 $0.00B (下一财年).
每股收益(EPS)历史表现: 2024: 实际 $-1.19 vs 预期 $-0.56 (不及预期 -112.5%). 2025: 实际 $-0.50 vs 预期 $-0.70 (超预期 +28.6%). 分析师准确度: 54%.
EPS 预测 — SILO
54%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$1.19
vs Est –$0.56
▼ 52.9% off
2025
Actual –$0.50
vs Est –$0.70
▲ 40.0% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
营收预测 — SILO
100%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.000B
vs Est $0.000B
▲ 0.1% off
2025
Actual $0.000B
vs Est $0.000B
▲ 0.1% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
